Peptide Agonists and Antagonists Explained: Receptor Activation, Competitive Inhibition and Functional Responses
Peptide Agonists and Antagonists: 7 Essential Receptor Mechanisms Explained
Peptide agonists and antagonists are molecules studied for their ability to activate receptors or alter receptor-mediated signalling. The distinction is fundamental to molecular pharmacology because binding to a receptor does not necessarily produce receptor activation.
A peptide may recognise and bind to a receptor yet produce little or no measurable functional response. Another peptide may activate the same receptor and initiate intracellular signalling. A third may reduce the response produced by an activating ligand.
These differences cannot be explained by binding affinity alone. peptide agonists and antagonists
Researchers distinguish agonists, antagonists and related ligand classes by examining how receptor binding influences measurable biological responses.
The classification depends on the receptor, experimental system, reference ligand and functional endpoint being studied. peptide agonists and antagonists
For example, a peptide may demonstrate agonist activity in a cyclic AMP assay while producing a different relative response in an arrestin-associated assay. Likewise, a ligand may behave as a partial agonist in one experimental system but appear closer to a full agonist in another because of differences in receptor expression or signalling amplification.
Understanding peptide agonists and antagonists therefore requires more than memorising definitions.
It requires examining receptor activation, efficacy, potency, concentration–response curves, competitive interactions and the limitations of experimental measurements.
This article explains seven important mechanisms that help researchers interpret peptide agonism and antagonism accurately.
It also examines why an antagonist is not necessarily an inverse agonist, why a partial agonist can reduce the response to a full agonist, and why changes in concentration–response curves must be interpreted using appropriate pharmacological models.
What Are Peptide Agonists and Antagonists?
A peptide agonist is a peptide ligand that binds to a receptor and produces a measurable receptor-mediated response in a defined experimental system.
A peptide antagonist is a peptide ligand that reduces or prevents a receptor-mediated response produced by an agonist, without necessarily activating that response itself.
The classification is based on functional behaviour rather than binding alone.
Peptide Agonists
Agonists promote receptor activation and associated signalling.
Their responses may be measured through intracellular messengers, phosphorylation events, transcriptional responses or other suitable endpoints.
Peptide Antagonists
Antagonists interfere with agonist-mediated responses. peptide agonists and antagonists
Some compete with an agonist for the same binding site, while others act through different mechanisms.
Receptor Binding Is Not Receptor Activation
Two peptides may bind to the same receptor with similar affinity but produce different functional outcomes.
This distinction is central to understanding peptide agonists and antagonists.
For additional background, see Peptide Receptors Explained and Peptide Binding Affinity.
1. Full Agonists Produce the Reference Maximal Response
A full agonist is a ligand capable of producing the maximal response of a defined receptor system under the conditions being examined.
The term does not mean that every receptor must be occupied.
Nor does it mean that the agonist produces the same absolute response in every cell or tissue.
Receptor Activation
When an agonist binds to a receptor, it may favour receptor conformations associated with signalling.
The resulting response depends on the receptor and its associated molecular machinery.
Full Agonism Is System-Dependent
A ligand classified as a full agonist in one experimental system may not produce an equivalent response in another. peptide agonists and antagonists
Differences may arise from receptor expression, signalling proteins or other cellular characteristics.
Maximal Response
The maximum measured response is often represented as Emax.
For a simple empirical concentration–response relationship:
[
E=E_0+\frac{(E_{\max}-E_0)[A]^n}{EC_{50}^{,n}+[A]^n}
]
Where:
- E is the observed response.
- E₀ is the baseline response.
- Emax is the upper asymptotic response.
- [A] is agonist concentration.
- EC50 is the concentration associated with half the response range.
- n is the Hill slope parameter.
This is an empirical model. Its parameters should not automatically be interpreted as direct molecular binding constants.
Hypothetical Example
Consider a receptor system in which a reference agonist produces a maximal normalised response of 100%.
A second peptide that reaches the same measured maximum under comparable conditions may also be classified as a full agonist in that assay.
Important Limitation
A normalised response of 100% is a comparison with the selected reference or system maximum.
It is not a universal measure of biological activity.
Key Lesson
Full agonism describes functional efficacy within a defined system, not an intrinsic guarantee of a particular biological outcome.
2. Partial Agonists Produce a Lower Maximal Response
A partial agonist activates a receptor but produces a lower maximal response than a full agonist in the same experimental system.
Partial agonists therefore possess agonist activity, but their measured efficacy is lower under the stated conditions.
Binding vs Activation
A partial agonist may bind strongly to a receptor without producing the same maximal functional response as a full agonist. peptide agonists and antagonists
Why Partial Agonism Occurs
The observed difference may reflect how the ligand influences receptor conformations and signalling processes.
However, the precise molecular explanation depends on the receptor system.
Hypothetical Comparison
| Parameter | Full agonist | Partial agonist |
|---|---|---|
| Binding Kd | 10 nM | 5 nM |
| Functional EC50 | 20 nM | 8 nM |
| Maximal normalised response | 100% | 45% |
All values are hypothetical.
Interpretation
The partial agonist demonstrates stronger equilibrium binding affinity and lower EC50 in the specified assays.
However, it produces a lower maximal response.
Can a Partial Agonist Reduce a Full Agonist Response?
Yes.
When both ligands compete for the same receptor population, a partial agonist can occupy receptors that would otherwise be occupied by a full agonist.
Under suitable conditions, this can reduce the overall response relative to that produced by the full agonist alone.
Why This Is Not Simple Antagonism
The partial agonist still produces receptor activation.
Its behaviour depends on the presence and concentration of other ligands and the experimental system.
Key Lesson
A partial agonist can produce agonist activity while functionally opposing a full agonist under particular conditions.
3. Neutral Antagonists Block Agonist Responses Without Negative Intrinsic Efficacy
A neutral antagonist binds to a receptor and prevents or reduces agonist-mediated activation without changing the receptor’s constitutive activity through inverse agonism.
This distinction matters when receptors display measurable activity in the absence of an added agonist.
Constitutive Receptor Activity
Some receptors can produce signalling activity without an externally added agonist.
The magnitude of this activity depends on the receptor and experimental system.
Neutral Antagonism
A neutral antagonist can interfere with agonist binding or activation while having no intrinsic effect on constitutive signalling in the relevant model. peptide agonists and antagonists
Experimental Observation
In an appropriate assay, a neutral antagonist may show little effect when tested alone.
However, it may reduce the response when an agonist is present.
Why Baseline Activity Matters
If the receptor has little measurable constitutive activity, neutral antagonists and inverse agonists may be difficult to distinguish using that assay.
Important Limitation
The absence of a detectable response from a ligand does not automatically establish neutral antagonism.
The assay must be capable of evaluating the relevant receptor activity.
Key Lesson
Neutral antagonists are distinguished by their functional properties, not simply by an absence of visible agonist activity.
4. Inverse Agonists Reduce Constitutive Receptor Activity
An inverse agonist reduces the constitutive activity of a receptor under conditions where that activity can be measured.
Unlike a neutral antagonist, an inverse agonist has negative efficacy relative to the constitutively active baseline in the specified system. peptide agonists and antagonists
Agonist vs Inverse Agonist
An agonist promotes a measurable receptor-mediated response.
An inverse agonist reduces constitutive signalling below its baseline.
Neutral Antagonist vs Inverse Agonist
A neutral antagonist does not itself reduce constitutive receptor activity in the relevant model.
An inverse agonist does.
Hypothetical Example
Consider a fictional receptor assay with the following normalised signals:
| Condition | Measured signal |
|---|---|
| Baseline constitutive activity | 30 units |
| Agonist present | 90 units |
| Neutral antagonist alone | 30 units |
| Inverse agonist alone | 12 units |
These values are illustrative.
Interpretation
The agonist increases the measured response above baseline.
The neutral antagonist does not change baseline activity in this example.
The inverse agonist reduces the constitutive response. peptide agonists and antagonists
Important Limitation
These distinctions depend on the receptor system and the assay’s ability to measure constitutive signalling.
Key Lesson
Inverse agonism is not simply stronger antagonism. It describes a different functional relationship with constitutive receptor activity.
5. Competitive Antagonists Can Shift Agonist Concentration–Response Curves
A competitive antagonist interacts with the same binding site as an agonist, or otherwise competes in a manner consistent with a defined competitive model.
For a simple reversible competitive antagonist at equilibrium, increasing agonist concentration can overcome the antagonist’s effect.
This is often described as surmountable antagonism.
Concentration–Response Curves
A concentration–response curve shows how the measured effect changes as agonist concentration increases.
Parallel Rightward Shift
Under the classical simple competitive model, adding a fixed antagonist concentration produces a parallel rightward shift in the agonist concentration–response curve.
The agonist requires a higher concentration to produce the same response.
The maximal response remains achievable.
Dose Ratio
The dose ratio compares the agonist concentrations required to produce the same response in the presence and absence of antagonist.
[
DR=\frac{EC_{50,,+B}}{EC_{50,,control}}
]
For an appropriate simple competitive system, the EC50 ratio may be used to estimate the dose ratio. peptide agonists and antagonists
Competitive Antagonism Relationship
For a simple reversible competitive antagonist:
[
DR=1+\frac{[B]}{K_B}
]
Where:
- DR is the dose ratio.
- [B] is the free antagonist concentration.
- KB is the antagonist equilibrium dissociation constant in the specified model.
Worked Example
Assume a hypothetical receptor assay gives:
- Agonist EC50 without antagonist = 10 nM.
- Agonist EC50 with antagonist = 40 nM.
Then:
[
DR=\frac{40}{10}=4
]
If the free antagonist concentration is 30 nM and the model assumptions are satisfied:
[
4=1+\frac{30}{K_B}
]
[
3=\frac{30}{K_B}
]
[
K_B=10\text{ nM}
]
Interpretation
The calculated antagonist equilibrium constant is 10 nM under the stated competitive model.
Important Limitations
This calculation assumes suitable equilibrium conditions, an appropriate competitive mechanism and a valid comparison of the functional curves.
Non-equilibrium conditions, complex signalling systems or other mechanisms may invalidate the simplified interpretation.
Key Lesson
Competitive antagonism can be characterised quantitatively, but a rightward shift alone does not prove that a ligand acts through a particular molecular mechanism.
6. Noncompetitive and Insurmountable Antagonism Require Different Interpretation
Not every antagonist produces a parallel rightward shift while preserving the maximal agonist response.
Some antagonists reduce the maximum response achievable under the experimental conditions.
This behaviour is often described as insurmountable antagonism.
However, insurmountable behaviour does not identify one unique molecular mechanism.
Noncompetitive Antagonism
In classical pharmacology, noncompetitive antagonism describes interference that cannot be overcome simply by increasing agonist concentration within the relevant model. peptide agonists and antagonists
Allosteric Interactions
An antagonist may bind to a receptor site distinct from the agonist’s primary binding site.
Such interactions can alter agonist binding or receptor activation.
Irreversible Binding
Some antagonists may form long-lasting or irreversible interactions with their targets.
Slow Dissociation
A slowly dissociating antagonist may appear insurmountable over the duration of a particular experiment.
Receptor Reserve
A system with spare receptors may maintain its maximal response despite some receptor inactivation.
Therefore, the same antagonist can produce different concentration–response patterns in different systems.
Experimental Interpretation
A reduced maximal response may be consistent with several mechanisms.
Additional experiments are required to distinguish them.
Key Lesson
The observed shape of an agonist concentration–response curve is informative, but it does not independently establish the antagonist’s binding mechanism.
7. Receptor Reserve and Signalling Amplification Influence Agonist Responses
Receptor reserve describes a situation in which the maximal functional response can be achieved without occupancy of the entire receptor population.
It is sometimes referred to as the presence of spare receptors. peptide agonists and antagonists
Receptor Occupancy
Occupancy describes the fraction of receptors bound by a ligand under defined conditions.
Functional Response
Functional response describes the measured biological effect.
Why They Differ
Receptor activation may initiate downstream signalling processes that amplify the initial molecular event.
Consequently, relatively low receptor occupancy may produce a substantial response.
EC50 vs Kd
For a simple binding system, Kd describes equilibrium dissociation.
EC50 describes functional potency in a particular assay.
These values need not be equal.
Hypothetical Example
A fictional peptide has:
- Binding Kd = 50 nM.
- Functional EC50 = 5 nM.
The lower EC50 may be consistent with signalling amplification or receptor reserve in the experimental system.
However, these data alone do not establish the precise mechanism.
Implications for Partial Agonists
A ligand classified as a partial agonist in a low-receptor-expression system may produce a larger relative response in a system with greater receptor reserve.
Implications for Antagonists
Receptor reserve can influence how receptor blockade affects the maximal response. peptide agonists and antagonists
Key Lesson
The experimental system influences how peptide agonists and antagonists are classified and compared.
For additional discussion, see Peptide Signalling Pathways.
Comparing the Main Receptor Ligand Classes
| Ligand class | Receptor interaction | Functional characteristic | Important distinction |
|---|---|---|---|
| Full agonist | Binds and activates receptor | Produces the reference maximal response | System-dependent efficacy |
| Partial agonist | Binds and activates receptor | Produces a lower maximal response | Can oppose a full agonist |
| Neutral antagonist | Binds and blocks agonist action | No intrinsic change in constitutive activity | Does not behave as an inverse agonist |
| Inverse agonist | Binds and reduces constitutive activity | Lowers baseline receptor signalling | Requires measurable constitutive activity |
| Reversible competitive antagonist | Competes under a suitable binding model | Typically causes a surmountable rightward shift | Maximum response may remain achievable |
| Insurmountable antagonist | Interferes with agonist response | May reduce achievable maximum | Multiple mechanisms can produce this pattern |
The categories are not always mutually exclusive. For example, a neutral antagonist may also be a reversible competitive antagonist.
Worked Example 1: Full Agonist vs Partial Agonist
Consider two fictional peptides examined in the same receptor assay.
| Agonist concentration | Full agonist response | Partial agonist response |
|---|---|---|
| 0 nM | 0% | 0% |
| 1 nM | 9% | 4.5% |
| 10 nM | 50% | 25% |
| 100 nM | 90.9% | 45.5% |
| 1,000 nM | 99.0% | 49.5% |
The values are hypothetical and follow simplified concentration–response relationships with EC50 = 10 nM for both ligands, Hill slope = 1 and different maximal responses.
Interpretation
The full agonist approaches a maximum of 100%.
The partial agonist approaches a maximum of 50%.
What Does This Demonstrate?
Both ligands can activate the receptor.
However, the partial agonist has lower maximal efficacy in the selected system.
What Does It Not Demonstrate?
The table does not establish the binding affinity of either peptide.
Key Lesson
Potency and efficacy are distinct properties when comparing peptide agonists and antagonists.
Worked Example 2: Competitive Antagonist Curve Shift
Consider a fictional receptor assay in which an agonist is tested with and without a fixed antagonist concentration. peptide agonists and antagonists
| Parameter | Agonist alone | Agonist with antagonist |
|---|---|---|
| EC50 | 8 nM | 32 nM |
| Maximum response | 100% | 100% |
| Hill slope | 1 | 1 |
These values are hypothetical.
Dose Ratio
[
DR=\frac{32}{8}=4
]
Interpretation
The antagonist produces a fourfold rightward shift without reducing the fitted maximum.
This pattern is consistent with simple surmountable competitive antagonism.
What Additional Evidence Is Needed?
A suitable concentration series of antagonist and appropriate model analysis would provide stronger support.
Key Lesson
A concentration–response shift can support mechanistic interpretation, but a single antagonist condition is not definitive proof.
Worked Example 3: Distinguishing Neutral Antagonism From Inverse Agonism
Consider a fictional receptor with measurable constitutive signalling.
| Experimental condition | Normalised signal |
|---|---|
| Receptor baseline | 25 |
| Agonist | 100 |
| Candidate Ligand A alone | 25 |
| Candidate Ligand B alone | 10 |
| Agonist plus Ligand A | 45 |
All values are illustrative.
Candidate Ligand A
Ligand A does not change baseline signalling when tested alone.
It reduces the agonist-associated response in the combination experiment.
This pattern is consistent with neutral antagonism under the selected conditions.
Candidate Ligand B
Ligand B reduces signalling below the constitutive baseline.
This is consistent with inverse agonism if the effect is receptor-mediated and appropriately controlled.
Important Limitation
Further experiments would be needed to confirm the mechanisms.
Key Lesson
The distinction between neutral antagonists and inverse agonists depends on their effects on constitutive receptor activity.
Schild Analysis and Antagonist Characterisation
Schild analysis is a classical method for examining antagonism through concentration–response relationships.
Under a simple competitive equilibrium model:
[
DR-1=\frac{[B]}{K_B}
]
Taking logarithms:
[
\log_{10}(DR-1)=\log_{10}[B]-\log_{10}K_B
]
Schild Plot
A Schild plot commonly relates log(DR − 1) to log antagonist concentration.
Slope
Under the ideal simple competitive model, the expected slope is 1.
pA2
pA2 is a classical pharmacological parameter associated with the negative logarithm of the molar antagonist concentration producing a dose ratio of 2 under the relevant conditions.
For a simple competitive antagonist with a unit Schild slope, pA2 corresponds to pKB.
Why the Slope Matters
A slope differing from unity may indicate that the simple model is inadequate.
However, deviations can arise from several experimental or mechanistic causes. peptide agonists and antagonists
Key Lesson
Schild analysis can help characterise antagonist behaviour, but valid conclusions require appropriate data and model assumptions.
Peptide Agonists and Antagonists in GPCR Research
Many peptide-responsive receptors belong to the G protein-coupled receptor family.
GPCR activation can influence intracellular signalling pathways. peptide agonists and antagonists
Gs-Associated Signalling
Some receptors engage pathways involving adenylyl cyclase and cyclic AMP.
Gi/o-Associated Signalling
Some receptors influence cyclic AMP production and other downstream processes through Gi/o-associated mechanisms.
Gq/11-Associated Signalling
Some receptors activate pathways involving phospholipase C and intracellular calcium mobilisation.
Arrestin-Associated Processes
Arrestins can participate in receptor regulation, trafficking and selected signalling processes.
Functional Selectivity
Different ligands may produce different relative signalling profiles through the same receptor.
Why This Matters
A ligand classified as an agonist in one pathway may exhibit different efficacy in another.
The classification should therefore identify the functional endpoint where relevant. peptide agonists and antagonists
For more detail, see Peptide Signalling Pathways and Peptide Selectivity.
How Researchers Identify Peptide Agonists and Antagonists
A useful experimental design distinguishes receptor binding from receptor-mediated function.
Binding Assays
Binding assays determine whether a ligand interacts with the selected target.
They do not independently establish agonism or antagonism.
Functional Agonist Assays
These assays measure whether the peptide produces a receptor-associated response when tested alone.
Functional Antagonist Assays
These assays examine whether the peptide changes the response produced by a reference agonist.
Constitutive Activity Assays
When measurable constitutive signalling exists, suitable assays may help distinguish neutral antagonists from inverse agonists. peptide agonists and antagonists
Concentration–Response Curves
Multiple concentrations help characterise potency, efficacy and curve-shift patterns.
Receptor-Specific Controls
Controls help determine whether observed responses are mediated by the intended receptor.
Orthogonal Measurements
Different assay types may help identify assay-specific artifacts or signalling differences. peptide agonists and antagonists
Replication
Independent experiments support reproducibility.
Analytical Characterisation
The tested peptide should be adequately characterised to support confidence in its molecular identity.
Related analytical guidance is available in Peptide Identity Testing and Peptide Quality Control Checklist.
Common Mistakes When Interpreting Peptide Agonists and Antagonists
1. Assuming Binding Proves Agonism
A ligand can bind without activating the receptor.
2. Treating Partial Agonists as Weak Antagonists
Partial agonists have intrinsic activating efficacy.
3. Confusing Neutral Antagonists With Inverse Agonists
Inverse agonists reduce constitutive receptor activity.
4. Assuming Every Rightward Shift Proves Competitive Antagonism
Additional evidence is needed to establish the mechanism.
5. Assuming Reduced Emax Always Means Irreversible Binding
Several mechanisms can produce an insurmountable response pattern.
6. Treating EC50 as a Direct Measure of Binding Affinity
EC50 depends on the functional assay and system.
7. Ignoring Receptor Reserve
Signalling amplification can influence potency and maximal responses.
8. Comparing Functional Results Across Different Systems Without Qualification
Receptor expression and signalling context can alter the observed ligand classification.
9. Assuming an Antagonist Has No Biological Effect
Blocking endogenous receptor signalling may still produce biological consequences.
10. Treating Molecular Pharmacology as Clinical Evidence
Receptor activity measurements do not independently establish human efficacy or safety.
Avoiding these errors improves the interpretation of peptide agonists and antagonists in laboratory research.
Practical Checklist for Reviewing an Agonist or Antagonist Study
| Review question | Why it matters |
|---|---|
| Was the receptor identified? | Defines the molecular target |
| Was peptide identity established? | Supports confidence in the tested ligand |
| Was binding measured separately from function? | Distinguishes affinity from efficacy |
| Was a suitable reference agonist included? | Supports relative efficacy comparisons |
| Were concentration–response curves generated? | Supports potency and maximum-response estimates |
| Was constitutive activity assessed where relevant? | Helps distinguish neutral and inverse agonism |
| Were antagonist concentrations varied? | Supports mechanism analysis |
| Were equilibrium assumptions considered? | Supports quantitative interpretation |
| Was receptor specificity examined? | Helps identify alternative mechanisms |
| Were uncertainty and replication reported? | Supports confidence in findings |
| Were conclusions limited to the experimental system? | Prevents unsupported extrapolation |
The strongest studies report what the ligand does, how the response was measured and which mechanisms the evidence supports.
Frequently Asked Questions About Peptide Agonists and Antagonists
1. What are peptide agonists and antagonists?
Peptide agonists activate receptors and produce measurable responses, while peptide antagonists reduce or prevent agonist-mediated receptor activation under defined conditions. peptide agonists and antagonists
2. What is a full peptide agonist?
A full agonist can produce the reference maximal response in a particular receptor system.
3. What is a partial peptide agonist?
A partial agonist activates a receptor but produces a lower maximal response than a full agonist in the same experimental system.
4. Can a partial agonist act like an antagonist?
A partial agonist can reduce the response to a full agonist when the ligands compete for the same receptor population under suitable conditions. peptide agonists and antagonists
5. What is a neutral antagonist?
A neutral antagonist reduces agonist-mediated activity without intrinsically changing constitutive receptor signalling in the relevant model. peptide agonists and antagonists
6. What is an inverse agonist?
An inverse agonist reduces constitutive receptor activity below its baseline in a system where such activity can be measured.
7. What is competitive antagonism?
Competitive antagonism involves a ligand opposing agonist action through an appropriate competitive binding mechanism, often producing a surmountable rightward shift in the agonist concentration–response curve.
8. What is the difference between competitive and noncompetitive antagonism?
Simple reversible competitive antagonism is generally surmountable by increasing agonist concentration, whereas noncompetitive antagonism cannot be overcome in the same way under the relevant model.
9. Does strong binding affinity mean a peptide is a strong agonist?
No. Binding affinity and functional efficacy are different properties.
10. How do researchers distinguish peptide agonists and antagonists?
Researchers use functional assays, concentration–response experiments, reference ligands, binding measurements and appropriate receptor-specific controls.
Conclusion: Understanding Peptide Agonists and Antagonists
Peptide agonists and antagonists are classified according to how they influence receptor-mediated responses, not simply whether they bind to a receptor.
Full agonists can produce the reference maximal response in a defined system. Partial agonists activate receptors with lower maximal efficacy. Neutral antagonists oppose agonist activity without reducing constitutive signalling, while inverse agonists decrease constitutive receptor activity. peptide agonists and antagonists
Competitive antagonists may produce surmountable rightward shifts in agonist concentration–response curves. Other mechanisms can alter maximal responses or produce more complex experimental patterns. peptide agonists and antagonists
These distinctions depend on receptor biology, signalling efficiency, ligand concentration and assay conditions.
For researchers, accurate interpretation requires separating binding affinity, potency, efficacy and antagonist mechanism.
A ligand’s classification should also remain specific to the receptor system and functional endpoint examined.
Understanding peptide agonists and antagonists provides an essential foundation for interpreting molecular pharmacology without assuming that receptor activity establishes clinical benefit or safety. peptide agonists and antagonists
Scientific References and Further Reading
- Kenakin, T. (2019). A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery. Fifth edition. Academic Press.
- Hulme, E. C., Trevethick, M. A. (2010). Ligand Binding Assays at Equilibrium: Validation and Interpretation. British Journal of Pharmacology, 161(6), 1219–1237.
https://doi.org/10.1111/j.1476-5381.2009.00604.x - Arunlakshana, O., Schild, H. O. (1959). Some Quantitative Uses of Drug Antagonists. British Journal of Pharmacology and Chemotherapy, 14(1), 48–58.
https://doi.org/10.1111/j.1476-5381.1959.tb00928.x - Black, J. W., Leff, P. (1983). Operational Models of Pharmacological Agonism. Proceedings of the Royal Society of London. Series B, 220(1219), 141–162.
https://doi.org/10.1098/rspb.1983.0093 - Urban, J. D., et al. (2007). Functional Selectivity and Classical Concepts of Quantitative Pharmacology. Journal of Pharmacology and Experimental Therapeutics, 320(1), 1–13.
https://doi.org/10.1124/jpet.106.104463 - Rosenbaum, D. M., Rasmussen, S. G. F., Kobilka, B. K. (2009). The Structure and Function of G-Protein-Coupled Receptors. Nature, 459, 356–363.
https://doi.org/10.1038/nature08144 - International Union of Basic and Clinical Pharmacology (IUPHAR). Guide to Pharmacology.
https://www.guidetopharmacology.org/ - National Center for Biotechnology Information (NCBI). PubMed Scientific Literature Database.
https://pubmed.ncbi.nlm.nih.gov/
These references provide foundational scientific information about receptor pharmacology, agonism, antagonism and concentration–response analysis. They do not establish the activity, safety, efficacy or regulatory status of any particular Axion Peptide Lab product.
Research information notice: This article is intended for scientific education and laboratory research. All numerical examples are hypothetical and do not represent experimental results for Axion Peptide Lab products. Receptor activation and antagonism measurements should not be interpreted as claims of clinical benefit or safety. Research peptides are not represented as suitable for human or veterinary administration.
One Response